1. Home
  2. MURA vs ELUT Comparison

MURA vs ELUT Comparison

Compare MURA & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • ELUT
  • Stock Information
  • Founded
  • MURA 2013
  • ELUT 2015
  • Country
  • MURA Ireland
  • ELUT United States
  • Employees
  • MURA N/A
  • ELUT N/A
  • Industry
  • MURA
  • ELUT Medical Specialities
  • Sector
  • MURA
  • ELUT Health Care
  • Exchange
  • MURA Nasdaq
  • ELUT Nasdaq
  • Market Cap
  • MURA 36.0M
  • ELUT 38.2M
  • IPO Year
  • MURA N/A
  • ELUT 2020
  • Fundamental
  • Price
  • MURA $2.10
  • ELUT $0.65
  • Analyst Decision
  • MURA Buy
  • ELUT Strong Buy
  • Analyst Count
  • MURA 2
  • ELUT 2
  • Target Price
  • MURA $6.00
  • ELUT $7.00
  • AVG Volume (30 Days)
  • MURA 112.3K
  • ELUT 224.2K
  • Earning Date
  • MURA 11-06-2025
  • ELUT 11-06-2025
  • Dividend Yield
  • MURA N/A
  • ELUT N/A
  • EPS Growth
  • MURA N/A
  • ELUT N/A
  • EPS
  • MURA N/A
  • ELUT N/A
  • Revenue
  • MURA N/A
  • ELUT $21,746,000.00
  • Revenue This Year
  • MURA N/A
  • ELUT $1.90
  • Revenue Next Year
  • MURA N/A
  • ELUT $6.37
  • P/E Ratio
  • MURA N/A
  • ELUT N/A
  • Revenue Growth
  • MURA N/A
  • ELUT 24.08
  • 52 Week Low
  • MURA $0.95
  • ELUT $0.66
  • 52 Week High
  • MURA $4.74
  • ELUT $5.12
  • Technical
  • Relative Strength Index (RSI)
  • MURA 51.21
  • ELUT 17.84
  • Support Level
  • MURA $2.06
  • ELUT $0.69
  • Resistance Level
  • MURA $2.10
  • ELUT $0.77
  • Average True Range (ATR)
  • MURA 0.02
  • ELUT 0.06
  • MACD
  • MURA -0.00
  • ELUT -0.01
  • Stochastic Oscillator
  • MURA 50.00
  • ELUT 2.86

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: